{
      "Rank": 325,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Approximately 1x10E6 MSC/kg",
            "Solution identical to experimental treatment, without the MSC"
      ],
      "ArmGroupInterventionName": [
            "Biological: Mesenchymal stromal cells",
            "Other: Placebo"
      ],
      "ArmGroupLabel": [
            "Mesenchymal Stromal cells",
            "Control group"
      ],
      "ArmGroupType": [
            "Experimental",
            "Placebo Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT04615429"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "A double-blind, randomized, controlled, clinical trial to evaluate the efficacy and safety of MSC (mesenchymal stromal cells) intravenous administration in patients with COVID-induced ARDS compared to a control arm."
      ],
      "BriefTitle": [
            "Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19"
      ],
      "CentralContactEMail": [
            "cavendano@salud.madrid.org",
            "concepcion.payares@salud.madrid.org"
      ],
      "CentralContactName": [
            "Cristina Avendano-Sola, MD, PhD",
            "Maria C Payares, MD, PhD"
      ],
      "CentralContactPhone": [
            "+34911916479"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact",
            "Contact"
      ],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "February 2022"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Acute Respiratory Distress Syndrome",
            "COVID-19 Pneumonia"
      ],
      "ConditionAncestorId": [
            "D000004194",
            "D000010335",
            "D000012141",
            "D000007239",
            "D000011024",
            "D000014777",
            "D000018352",
            "D000003333",
            "D000030341",
            "D000012327",
            "D000008171",
            "D000012140",
            "D000012120",
            "D000007235",
            "D000007232",
            "D000055370"
      ],
      "ConditionAncestorTerm": [
            "Disease",
            "Pathologic Processes",
            "Respiratory Tract Infections",
            "Infections",
            "Pneumonia, Viral",
            "Virus Diseases",
            "Coronavirus Infections",
            "Coronaviridae Infections",
            "Nidovirales Infections",
            "RNA Virus Infections",
            "Lung Diseases",
            "Respiratory Tract Diseases",
            "Respiration Disorders",
            "Infant, Premature, Diseases",
            "Infant, Newborn, Diseases",
            "Lung Injury"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC01",
            "BC08",
            "All",
            "BC23",
            "BC16",
            "BC26",
            "BXS",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Infections",
            "Respiratory Tract (Lung and Bronchial) Diseases",
            "All Conditions",
            "Symptoms and General Pathology",
            "Diseases and Abnormalities at or Before Birth",
            "Wounds and Injuries",
            "Urinary Tract, Sexual Organs, and Pregnancy Conditions",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "COVID-19",
            "Syndrome",
            "Respiratory Distress Syndrome",
            "Pneumonia",
            "Respiratory Distress Syndrome",
            "Acute Respiratory Distress Syndrome",
            "Respiratory Distress Syndrome",
            "Acute Respiratory Distress Syndrome"
      ],
      "ConditionBrowseLeafId": [
            "M2562",
            "M15507",
            "M14117",
            "M13056",
            "M14116",
            "M27297",
            "M19643",
            "M27296",
            "M9435",
            "M14130",
            "M5520",
            "M13066",
            "M16674",
            "M5707",
            "M22838",
            "M14301",
            "M10320",
            "M14129",
            "M14109",
            "M25022",
            "M9431",
            "M9428",
            "T4927",
            "T192",
            "T170"
      ],
      "ConditionBrowseLeafName": [
            "COVID-19",
            "Syndrome",
            "Respiratory Distress Syndrome",
            "Pneumonia",
            "Respiratory Distress Syndrome, Newborn",
            "Acute Lung Injury",
            "Coronavirus Infections",
            "Lung Injury",
            "Infections",
            "Respiratory Tract Infections",
            "Communicable Diseases",
            "Pneumonia, Viral",
            "Virus Diseases",
            "Coronaviridae Infections",
            "Nidovirales Infections",
            "RNA Virus Infections",
            "Lung Diseases",
            "Respiratory Tract Diseases",
            "Respiration Disorders",
            "Premature Birth",
            "Infant, Premature, Diseases",
            "Infant, Newborn, Diseases",
            "Respiratory Distress Syndrome, Infant",
            "Acute Respiratory Distress Syndrome",
            "Acute Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "high",
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "high",
            "high",
            "low"
      ],
      "ConditionMeshId": [
            "D000086382",
            "D000011014",
            "D000012128",
            "D000012127",
            "D000055371",
            "D000013577"
      ],
      "ConditionMeshTerm": [
            "COVID-19",
            "Pneumonia",
            "Respiratory Distress Syndrome",
            "Respiratory Distress Syndrome, Newborn",
            "Acute Lung Injury",
            "Syndrome"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Double"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Investigator"
      ],
      "DetailedDescription": [
            "A double-blind, randomized, controlled, clinical trial to evaluate the efficacy and safety of MSC (mesenchymal stromal cells) intravenous administration in patients with COVID-induced ARDS compared to a control arm.\n\nAll trial participants will receive SOC*.\n\nRandomization will be 1:1 between:\n\nTreatment arm: allogenic MSC.\n\nControl arm: Placebo (solution with the same composition as the experimental treatment, without the MSC).\n\nSOC can include any medicines that are being used in clinical practice (e.g. lopinavir/ritonavir; hydroxy/chloroquine, tocilizumab, etc.)."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nInformed consent prior to performing study procedures (witnessed oral consent with written consent by representatives will be accepted to avoid paper handling). Written consent by patient or representatives will be obtained whenever possible.\nAdult patients \u226518 years of age at the time of enrolment.\nLaboratory-confirmed SARS-CoV-2 infection as determined by PCR, in oropharyngeal swabs or any other relevant specimen obtained during the course of the disease. Alternative tests (e.g., rapid antigenic tests) are also acceptable as laboratory confirmation if their specificity has been accepted by the Sponsor.\nModerate to severe ARDS (PaO2/FiO2 ratio equal or less than 200 mmHg) for less than 96 hours at the time of randomization.\nPatients requiring invasive ventilation are eligible within 72 hours from intubation.\nEligible for ICU admission, according to the clinical team.\n\nExclusion Criteria:\n\nImminent and unavoidable progression to death within 24 hours, irrespective of the provision of treatments (in the opinion of the clinical team).\n\"Do Not Attempt Resuscitation\" order in place.\nAny end-stage organ disease or condition, which in the investigator's opinion, makes the patient an unsuitable candidate for treatment.\nHistory of a moderate/severe lung disorder requiring home-based oxygen therapy.\nPatient requiring ECMO, hemodialysis or hemofiltration at the time of treatment administration.\nCurrent diagnosis of pulmonary embolism.\nActive neoplasm, except carcinoma in situ or basalioma.\nKnown allergy to the products involved in the allogenic MSC production process.\nCurrent pregnancy or lactation (women with childbearing potential should have a negative pregnancy test result at the time of study enrollment).\nCurrent participation in a clinical trial with an experimental treatment for COVID-19 (the use of any off-label medicine according to local treatment protocols is not an exclusion criteria).\nAny circumstances that in the investigator's opinion compromises the patient's ability to participate in the clinical trial."
      ],
      "EnrollmentCount": [
            "20"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Mesenchymal Stromal cells",
            "Control group"
      ],
      "InterventionBrowseBranchAbbrev": [
            "PhSol",
            "All"
      ],
      "InterventionBrowseBranchName": [
            "Pharmaceutical Solutions",
            "All Drugs and Chemicals"
      ],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [
            "M21013"
      ],
      "InterventionBrowseLeafName": [
            "Pharmaceutical Solutions"
      ],
      "InterventionBrowseLeafRelevance": [
            "low"
      ],
      "InterventionDescription": [
            "Administration of one single dose of allogenic Mesenchymal stromal cells",
            "Administration of placebo (solution identical to experimental treatment, without the MSC)"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "Mesenchymal stromal cells",
            "Placebo"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological",
            "Other"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Acute Respiratory Distress Syndrome",
            "COVID-19 Pneumonia",
            "Mesenchymal stromal cells",
            "Coronavirus",
            "SARS-CoV-2"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "November 10, 2021"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "November 9, 2021"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Cristina Avenda\u00f1o Sol\u00e1"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Majadahonda"
      ],
      "LocationContactEMail": [
            "rduarte.work@gmail.com"
      ],
      "LocationContactName": [
            "Rafael F Duarte, MD, PhD",
            "Rafael F Duarte, MD, PhD",
            "Juan J Rubio, MD, PhD",
            "Rosa Malo, MD"
      ],
      "LocationContactPhone": [
            "+34911916662"
      ],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [
            "Contact",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator"
      ],
      "LocationCountry": [
            "Spain"
      ],
      "LocationFacility": [
            "Hospital Universitario Puerta de Hierro-Majadahonda"
      ],
      "LocationState": [
            "Madrid"
      ],
      "LocationStatus": [
            "Recruiting"
      ],
      "LocationZip": [
            "28222"
      ],
      "MaximumAge": [],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Double-blind, Randomized, Controlled, Clinical Trial to Assess the Efficacy of Allogenic Mesenchymal Stromal Cells in Patients With Acute Respiratory Distress Syndrome Due to COVID-19"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Puerta de Hierro University Hospital"
      ],
      "OrgStudyId": [
            "COVID-AT"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [
            "Exploratory endpoint Analytical markers (e.g., neutrophil and lymphocyte counts). Changes from baseline to set time points will be calculated."
      ],
      "OtherOutcomeMeasure": [
            "Analytical endpoints"
      ],
      "OtherOutcomeTimeFrame": [
            "Baseline and days 2, 4, 7, 14 and 28 after treatment"
      ],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Hematology Department. Hospital Universitario Puerta de Hierro",
            "Clinical Pharmacology Department. Hospital Universitario Puerta de Hierro",
            "ICU. Hospital Universitario Puerta de Hierro",
            "Respiratory Medicine Department"
      ],
      "OverallOfficialName": [
            "Rafael F Duarte, MD, PhD",
            "Cristina Avedano-Sola, MD, PhD",
            "Juan J Rubio, MD, PhD",
            "Rosa Malo, MD"
      ],
      "OverallOfficialRole": [
            "Study Chair",
            "Study Chair",
            "Principal Investigator",
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Recruiting"
      ],
      "OversightHasDMC": [
            "No"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "January 2022"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "Primary endpoint"
      ],
      "PrimaryOutcomeMeasure": [
            "Change in the PaO2/FiO2* ratio from baseline to day 7 of treatment administration"
      ],
      "PrimaryOutcomeTimeFrame": [
            "7 days"
      ],
      "ReferenceCitation": [
            "Payares-Herrera C, Mart\u00ednez-Mu\u00f1oz ME, Vallhonrat IL, de Molina RM, Torres MP, Trisan A, de Diego IS, Alonso R, Zafra R, Donaire T, S\u00e1nchez R, Rubio JJ, Duarte Palomino RF, Sol\u00e1 CA. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial. Trials. 2021 Jan 6;22(1):9. doi: 10.1186/s13063-020-04964-1."
      ],
      "ReferencePMID": [
            "33407777"
      ],
      "ReferenceType": [
            "derived"
      ],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [
            "Puerta de Hierro University Hospital"
      ],
      "ResponsiblePartyInvestigatorFullName": [
            "Cristina Avenda\u00f1o Sol\u00e1"
      ],
      "ResponsiblePartyInvestigatorTitle": [
            "Head of Clinical Pharmacology Deptarment"
      ],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor-Investigator"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [
            "2020-002193-27"
      ],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [
            "EudraCT Number"
      ],
      "SecondaryOutcomeDescription": [
            "Secondary endpoint",
            "Secondary endpoint",
            "Secondary endpoint.\n\nCategories:\n\nNot hospitalized, no limitations on activities.\nNot hospitalized, limitation on activities.\nHospitalized, not requiring supplemental oxygen.\nHospitalized, requiring supplemental oxygen.\nHospitalized, on non-invasive ventilation or high flow oxygen devices.\nHospitalized, on invasive mechanical ventilation or ECMO .\nDeath.",
            "Secondary endpoint",
            "Secondary endpoint Sequential Organ Failure Assessment score (0-24)",
            "Secondary endpoint",
            "Secondary endpoint",
            "Secondary endpoint",
            "Secondary endpoint Proportion of patients with non-invasive ventilation",
            "Secondary endpoint Proportion of patients with invasive mechanical ventilation",
            "Secondary endpoint (number of days)",
            "Secondary endpoint (number of days)",
            "Secondary endpoint",
            "Secondary endpoint",
            "Secondary endpoint"
      ],
      "SecondaryOutcomeMeasure": [
            "All-cause mortality",
            "Time to PaO2/FiO2 ratio greater than 200 mmHg",
            "Clinical status on the World Health Organization ordinal scale",
            "PaO2/FiO2 ratio",
            "SOFA score",
            "Oxygen therapy-free days",
            "Duration of hospitalization",
            "Duration of ICU admission",
            "Incidence of non-invasive ventilation",
            "Incidence of invasive mechanical ventilation",
            "Duration of non-invasive ventilation",
            "Duration of invasive mechanical ventilation",
            "Mechanical ventilation-free days",
            "Survival rate",
            "Cumulative incidence SAEs, Grade 3 and 4 AEs, ADR and AEs of special interest."
      ],
      "SecondaryOutcomeTimeFrame": [
            "Days 7, 14, and 28 after treatment",
            "12 months",
            "Baseline, daily until day 14, and on day 28 after treatment",
            "Baseline and days 2, 4, 14 and 28 after treatment",
            "Baseline and days 2, 4, 7, 14 and 28 after treatment",
            "Day 28",
            "12 months",
            "12 months",
            "Day 28",
            "Day 28",
            "Day 28",
            "Day 28",
            "Day 28",
            "3 and 12 months.",
            "12 months"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "September 15, 2020"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "November 2021"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "November 4, 2020"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "October 25, 2020"
      ],
      "StudyFirstSubmitQCDate": [
            "November 2, 2020"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}